Evaluation of a Live Attenuated Human Metapneumovirus Vaccine in Adults and Children
Authors:
Open Access
- 21 April 2017
- journal article
- research article
- Published by Oxford University Press (OUP) in Journal of the Pediatric Infectious Diseases Society
- Vol. 7 (1) , 86-89
Abstract
We conducted a phase I clinical trial of an experimental live attenuated recombinant human metapneumovirus (HMPV) vaccine (rHMPV-Pa) sequentially in adults, HMPV-seropositive children, and HMPV-seronegative children, the target population for vaccination. rHMPV-Pa was appropriately restricted in replication in adults and HMPV-seropositive children but was overattenuated for HMPV-seronegative children.Keywords
Funding Information
- National Institute of Allergy and Infectious Diseases
This publication has 16 references indexed in Scilit:
- New Approaches for Immunization and Therapy against Human MetapneumovirusClinical and Vaccine Immunology, 2015
- Community-Acquired Pneumonia Requiring Hospitalization among U.S. ChildrenNew England Journal of Medicine, 2015
- Live-Attenuated Respiratory Syncytial Virus Vaccines2013
- Safety and infectivity of two doses of live-attenuated recombinant cold-passaged human parainfluenza type 3 virus vaccine rHPIV3cp45 in HPIV3-seronegative young childrenVaccine, 2013
- Progress in the development of human parainfluenza virus vaccinesExpert Review of Respiratory Medicine, 2011
- Rates of hospitalisation for influenza, respiratory syncytial virus and human metapneumovirus among infants and young childrenVaccine, 2006
- Chimeric Recombinant Human Metapneumoviruses with the Nucleoprotein or Phosphoprotein Open Reading Frame Replaced by That of Avian Metapneumovirus Exhibit Improved Growth In Vitro and Attenuation In VivoJournal of Virology, 2005
- Presence of the new human metapneumovirus in French children with bronchiolitisThe Pediatric Infectious Disease Journal, 2003
- A newly discovered human pneumovirus isolated from young children with respiratory tract diseaseNature Medicine, 2001
- Safety and immunogenicity of a cold-adapted influenza A (H1N1) reassortant virus vaccine administered to infants less than six months of ageThe Pediatric Infectious Disease Journal, 1995